Hey Neurohacker,

58 signals. That's over a year of running this newsletter, and a year of you tuning in each week, even if it was just to skim the section relevant to you. Thank you. That's the part I want to lead with, because it's the part I'm most certain about.

What I'm less certain about is the format. Weekly cadence built the habit, but it also built a ceiling. I want to focus on building depth and substance without forcing a weekly cadence.

So the NeuroCircuit is going on pause while I figure out what the next version should be. And rather than guess, I'd rather hear from you. What did you actually use this newsletter for? What would have made it more valuable? What kind of piece would make you stop scrolling and read end to end? Reply to this email with whatever comes to mind. The honest reader notes will shape what comes back better than anything I could decide alone.

Until then, thank you again for a year of attention I didn't take for granted. Keep building.

Ricardo

✦ This Week's Partner: Wispr Flow

Neurotechnology News | May 9–22, 2026

Let's cut through the noise.

This week, SetPoint's vagus nerve stimulation cleared a health-economics bar in rheumatoid arthritis. Industry capital flowed toward less-invasive brain interfaces (Mobia's $150M initial public offering, Oman backing Neuralink, fresh rounds for BlueWind, Ampa, and Neurosoft) while China's NEO brain-computer interface moved into commercial use. Bottom line: regulators and investors are picking smaller-footprint architectures faster than the channel-count race expected.

⚡ Signal of the Week

Meta AI released NeuralBench, the first standardized benchmark for NeuroAI models.

Published: May 6, 2026
Read more ➡️ NeuralBench release / Meta AI publications page

The framework wraps 36 electroencephalography (EEG) downstream tasks across 94 public datasets behind one interface, with 9,478 subjects and 13,603 hours of recordings. The headline finding cuts hard against current narrative: foundation models only marginally outperform task-specific models, and cognitive decoding plus clinical predictions remain effectively unsolved. This matters more than the week's FDA action because it hands every working engineer a runnable artifact (pip install neuralbench, MIT license) that can falsify or validate the foundation-model thesis driving capital into the space. The first credible standard usually locks in the field's evaluation conventions.

Published: May 2026
Read more ➡️SetPoint Medical

SetPoint reported that neuroimmune modulation via implanted vagus nerve stimulation (VNS) reduced total cost of care and improved quality of life versus standard pharmacologic management in rheumatoid arthritis (RA). The release tracks the same therapeutic concept Galvani Bioelectronics has now abandoned (see Industry).

💡 Big Picture: A health-economics result lands in the same window as Galvani's wind-down, which inverts the storyline: the indication is viable, but only inside the focused-startup operating model, not the pharma joint-venture one.

Published: May 7, 2026 (priced); closed May 11, 2026
Read more ➡️ MSN/MedTech Dive / Investor Relations

Mobia priced a $150M initial public offering (IPO) at $15 per share on the Nasdaq Global Select Market under ticker MOBI, with BofA Securities, J.P. Morgan, and Goldman Sachs as lead bookrunners. The company markets the Vivistim Paired Vagus Nerve Stimulation System for upper-limb impairment after chronic ischemic stroke and plans to deploy roughly $93.5M into commercial expansion.

💡 Big Picture: Public-market validation of paired vagus nerve stimulation reframes neuromodulation in stroke from a niche category into a sales-execution problem, which raises the bar for clinical evidence required from any future entrants in the same indication.

Published: May 6, 2026
Read more ➡️ Fast Company Middle East / Times of Oman

The Oman Investment Authority disclosed a strategic equity investment in Neuralink, with value not made public. Neuralink reports 21 patients implanted as of January 2026 (17 in calendar 2025) and a stated target of 1,000 implant procedures by year-end 2026.

💡 Big Picture: Sovereign-wealth capital entering invasive brain-computer interface (BCI) at this stage signals a shift in funder profile from venture capital to balance-sheet investors, which usually precedes either an IPO window or a delayed one funded by patient capital.

Published: May 14, 2026
Read more ➡️ BusinessWire press release

BlueWind raised $47.8M to scale commercial deployment of Revi, a leadless tibial nerve stimulator for urge urinary incontinence and overactive bladder (OAB). The capital targets sales-force expansion and reimbursement work rather than further pivotal trials.

💡 Big Picture: Peripheral neuromodulation is bifurcating into a clinical track (still scaling trials) and a commercial track (scaling sales infrastructure), and Revi is now firmly in the second category.

Published: May 14, 2026
Read more ➡️ PR Newswire / FinSMEs

Ampa closed an oversubscribed round bringing total capital above $25M, with Morningside Ventures, Trimera Capital, and Tim Ferriss participating. The FDA-cleared Ampa One transcranial magnetic stimulation (TMS) device runs at $3,000 per month per clinic, fits in a car trunk, and operates with a few hours of staff training.

💡 Big Picture: Ampa is unbundling TMS from the dedicated psychiatric-suite footprint that has constrained adoption for a decade, which changes the unit economics from real-estate-bound to per-treatment-variable.

Published: May 19, 2026
Read more ➡️ Nature news / ClinicalTrials.gov

Following the March National Medical Products Administration (NMPA) Class III commercial approval, NEO is now expanding into operational use, with an ALS-targeted brain-controlled wheelchair scheduled for June 2026 launch. NEO uses a semi-invasive epidural array (no cortex penetration) paired with a pneumatic robotic glove, enrolled 36 patients across 11 lead centers, and is approved for adults aged 18–60 with cervical spinal cord injury who retain some upper-arm function.

💡 Big Picture: The first invasive BCI to clear a national regulator did so with epidural electrodes and a constrained motor effector, not high-density intracortical recording, which reframes the western "more channels equals more capability" thesis as a regulatory liability rather than a moat.

Published: May 20, 2026
Read more ➡️ BusinessWire

Geneva-based Neurosoft raised $7.5M led by Skybound Venture Capital, taking total capital above $20M, with 10 human implants completed across two trials targeting tinnitus and epilepsy. Company claims, not independently benchmarked, put the proprietary soft electrodes at roughly 1,000 times more compliant and covering 30 times more cortex than competing flexible neural interfaces.

💡 Big Picture: Adding stretchable epicortical hardware to the field's active architecture set (intracortical microneedle, thin-film epicortical, endovascular stentrode) confirms there is no convergence toward one winning electrode modality, which means decoders increasingly need to be hardware-agnostic to survive a heterogeneous deployment landscape.

Published: May 1, 2026
Read more ➡️ MassDevice / Securities and Exchange Commission filing

Inspire reported Q1 2026 revenue of $204.6M (up 1.6% year over year) and narrowed full-year guidance to $825–875M (down 4–10% versus 2025) on Inspire V coding and reimbursement uncertainty, plus implementation of the WISeR utilization-management program. The company expects challenges to persist through 2026 and a return to growth in 2027.

💡 Big Picture: Reimbursement architecture, not device performance, is now the dominant variable in established neuromodulation revenue, which raises the implicit hurdle for any new entrant whose business case assumes a smooth coding pathway.

Published: May 13, 2026
Read more ➡️MassDevice / BusinessWire

The FDA cleared Epineuron's handheld Evala device for intraoperative electrical stimulation, providing surgeons with nerve identification and functional evaluation across nerve sizes. Evala extends Epineuron's PeriPulse bioelectronic platform for peripheral nerve care.

💡 Big Picture: Surgical-tool 510(k) pathway clearances are a quiet leading indicator for the data infrastructure (intraoperative nerve maps, surgical telemetry) that the next generation of closed-loop peripheral neuromodulation will train on.

Every viable BCI architecture in clinical use today (intracortical microneedle, thin-film epicortical, stretchable epicortical, endovascular stentrode, epidural array) is being differentiated less by raw signal quality and more by which regulator will credential which surgical-risk profile for which patient population. When the FDA, NMPA, and EU MDR are effectively picking the winners, what does that imply for builders whose technical roadmap optimizes for channel count and bandwidth?

You don't send a colleague a three-word brief. You explain the context, the constraints, what you've already tried. But typing all that into ChatGPT takes forever — so you don't.

Wispr Flow lets you speak your prompts instead. Talk through your thinking naturally and get clean, paste-ready text. No filler words. No cleanup. Just detailed prompts that actually get you useful answers on the first try.

Millions of users worldwide. Works system-wide on Mac, Windows, and iPhone.

Try Wispr Flow free